Hetacillin

Summary

Hetacillin (CHEMBL1201116) is an approved small-molecule antibacterial drug (ATC J01CA18); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA18
• Indications: 1 condition
• Chemistry: 389.5 Da · C19H23N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201116
Name	Hetacillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	443387
ChEBI	CHEBI:5683
ATC	J01CA18
Molecular formula	C19H23N3O4S
Molecular weight	389.5
InChIKey	DXVUYOAEDJXBPY-NFFDBFGFSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: BL-P 804, BL-P-804, BLP-804, BRL-804, Hetacilina, Hetacillin, Hetacillin acid, Hetacilline, Hetacin, Versapen, HETACILLIN, HETACILLINE

Parent form; salt/anhydrous children: CHEMBL1201121

Patent coverage: 1,981 distinct patent families (7,644 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).